B+
Bull case
30%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
NTLA
Intellia TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+87.1
Score
AI commentary
The company-confirmed Priority Review is positive, but the October 1 $12.12 anchor does not establish the announcement-day market reaction. The September AI-related headlines are secondary and do not establish a change in Intellia's clinical outlook. Verified analyst revisions, options positioning, short interest and sufficient social coverage are unavailable; zero-valued sentiment fields mean unavailable, not neutral. Low market-coverage visibility warrants monitoring rather than a high-conviction call.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventNex-z Phase 3 enrollmentHigh impact
Intellia reported resumed Phase 3 enrollment and expected MAGNITUDE-2 enrollment in ATTRv-PN to finish in the second half of 2026. Completion would help preserve pipeline value beyond lonvo-z; renewed delay or safety concerns would undermine it [#SEC-8K-2026-08-06]. Nex-z is under a verified co-development arrangement with Regeneron [#REL-343891cf-00b2-4832-bd4d-b9c85fe099f3].
2027-03-10eventLonvo-z FDA decisionHigh impact
The FDA accepted the hereditary-angioedema BLA, granted Priority Review and set a March 10, 2027 target action date. The FDA was not planning an advisory committee as of Intellia's September 8 announcement. Approval remains a binary outcome, not an assurance [#8-K-2026-09-08].
2027-06-30catalystPotential lonvo-z U.S. launchHigh impact
HAELO showed an 87% reduction in mean monthly attacks versus placebo over its six-month efficacy period. Intellia anticipated a first-half 2027 U.S. launch if approved; reimbursement, treatment-center readiness and uptake remain unproven [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology